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ABSTRACT
Introduction: β Blockers are important treatment for
ischaemic heart disease and heart failure; however,
there has long been concern about their use in people
with chronic obstructive pulmonary disease (COPD)
due to fear of symptomatic worsening of
breathlessness. Despite growing evidence of safety and
efficacy, they remain underused. We examined the
effect of β-blockade on lung function, exercise
performance and dynamic hyperinflation in a group of
vascular surgical patients, a high proportion of who
were expected to have COPD.
Methods: People undergoing routine abdominal aortic
aneurysm (AAA) surveillance were sequentially
recruited from vascular surgery clinic. They completed
plethysmographically measured lung function and
incremental cardiopulmonary exercise testing with
dynamic measurement of inspiratory capacity while
taking and not taking β blocker.
Results: 48 participants completed tests while taking
and not taking β blockers with 38 completing all
assessments successfully. 15 participants (39%) were
found to have, predominantly mild and undiagnosed,
COPD. People with COPD had airflow obstruction,
increased airway resistance (Raw) and specific
conductance (sGaw), static hyperinflation and
dynamically hyperinflated during exercise. In the whole
group, β-blockade led to a small fall in FEV1 (0.1 L/
2.8% predicted) but did not affect Raw, sGaw, static or
dynamic hyperinflation. No difference in response to
β-blockade was seen in those with and without COPD.
Conclusions: In people with AAA, β-blockade has
little effect on lung function and dynamic hyperinflation
in those with and without COPD. In this population, the
prevalence of COPD is high and consideration should
be given to case finding with spirometry.
Trial registration number: NCT02106286.
INTRODUCTION
β Blockers represent an important treatment
for heart failure and have been shown to
reduce mortality and symptoms.1 In addition,
β blockers are an important part of treat-
ment postmyocardial infarction (MI) where
again they are associated with reduced mor-
tality including in people with chronic
obstructive pulmonary disease (COPD).2
However, there has long been concern that β
blockers may worsen lung function3 and
could be associated with increased mortality
in people with severe COPD.4 Heart failure
guidelines recommend their use stating
that COPD is not a contraindication to
β-blockade5 and a body of evidence now
exists suggesting that cardioselective β block-
ers are not detrimental to people with COPD
rather their prescription is associated with a
survival beneﬁt post-MI,6 in chronic heart
failure7 and overall.8 There is also a sug-
gestion that the use of β blockers is asso-
ciated with fewer disease exacerbations.8–11
However, it is clear that β blockers are still un-
derused in people with COPD12 because of
fears of worsening lung function, associated
with increased symptoms, secondary to para-
sympathetic bronchoconstriction.
A number of studies, using a variety of car-
dioselective and non-cardioselective β block-
ers, have assessed the short-term effect of
β-blockade on FEV1 and meta-analyses
show no effect or small, but relatively insig-
niﬁcant, falls in FEV1.
13 14 However, most
studies report the effect of β blockers on spir-
ometry only and there is a lack of data on
other lung function measures, in particular
body plethysmographic data. To the best of
our knowledge, only one prospective study
has examined the effect of β blockers on
dynamic hyperinﬂation and peak exercise
capacity.15 This is important because there is
a relatively weak relationship between FEV1,
symptoms and exercise capacity, in people
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with COPD, which may explain the reluctance to pre-
scribe. Moreover, it is recognised that COPD is under-
diagnosed16 and this may contribute to reluctance to
use β blockers in long-term cigarette smokers.
We have recently published a study examining the
effect of perioperative β-blockade on cardiopulmonary
exercise performance in people with abdominal aortic
aneurysm (AAA) awaiting surgery.17 We showed improve-
ment in exercise performance when people were taking
β blockers. As a ‘real life’ study, a signiﬁcant number of
participants had (mainly undiagnosed and relatively
mild) COPD. As part of this study, we examined the
effect of β-blockade on lung function, including body
plethysmography and dynamic hyperinﬂation, during
exercise testing. We hypothesised that β-blockade would
have little effect on these parameters in the overall
group, but there would be a greater effect on airway
resistance, speciﬁc conductance and dynamic hyperinﬂa-
tion in those participants with COPD.
METHODS
Participants
Between April 2012 and August 2013, participants were
recruited from a cohort attending our vascular labora-
tory for routine AAA surveillance (<5.5 cm aneurysm).
We approached all patients >18 years who were able to
perform a cardiopulmonary exercise test (CPET) and
excluded patients who had a known contraindication to
β blockers, severe ischaemic heart disease, stage IV–V
chronic kidney disease, uncontrolled hypertension,
those unable to consent and absolute contraindications
to CPET based on the ATS/ACCP guidelines.18
Participants were neither selected for the presence or
absence of COPD nor use of β blockers. Written
informed consent was obtained from all patients.
Study design
Patients were divided into two groups based on whether
they were normally taking β blockers (chronic β block-
ade) or not (acute β blockade). All patients completed
the study protocol both ‘on’ and ‘off’ β blockers.
Patients already taking β blockers completed tests at visit
1 taking their usual prescription and repeated tests at
visit 2 having stopped β blocker for at least 7 days.
Patients not normally taking β blockers completed tests
at visit 1 ‘off’ β blockers and then started bisoprolol, a
cardioselective β blocker, once daily—1.25 mg if weight
50–75 kg, 2.5 mg if 76–100 kg and 3.75 mg if 101 kg or
heavier. Doses were not titrated to achieve a target heart
rate. Participants then repeated tests at visit 2 at least
48 hours after starting bisoprolol. All participants were
advised of the potential risks of alteration of their
medical therapy at the time of consent.
Demographics details and health and medication
information was collected. At each visit, participants
completed lung function measurements, including spir-
ometry, lung volumes, gas transfer and airway resistance
using body plethysmography (Zan Messgerate, nSpire
Health 530). The small number of participants already
diagnosed with airway disease were asked to omit short-
acting bronchodilators for 6 hours and long-acting
bronchodilators (β-agonists and antimuscarinics) for 12
or 24 hours, according to the bronchodilator taken nor-
mally. All measurements were performed according to
ERS/ATS guidelines.19 Study participants performed
incremental CPET, following a standard protocol, and
these results have been published previously.17
Inspiratory capacity (IC) was measured before exercise
and then every minute during exercise with a ﬁnal IC
measurement at peak exercise.20 Isotime IC was used for
analysis. Borg score of breathlessness and leg fatigue was
also measured at rest and then every minute during
exercise and recovery.21
Assessment of the impact of β-blockade on lung func-
tion parameters and dynamic hyperinﬂation (dynamic
IC measurements) was a predeﬁned study outcome.
Subgroup analysis according to the presence or absence
of COPD was performed post hoc when it was estab-
lished that a signiﬁcant number of study participants
had (predominantly undiagnosed) COPD.
In the absence of postbronchodilator measures of
lung function and to avoid overdiagnosis of COPD in
older participants (particularly men), the diagnosis of
COPD was based on a minimum 10 pack years cigarette
smoking and a prebronchodilator FEV1/FVC ratio
exceeding the lower limit of normal using GLI-2012
equations.22 Airﬂow obstruction was deﬁned as a stand-
ard residual z-score of below −1.64.
Statistical methods
Patient demographics have been summarised as mean
(SD) for continuous variables or median (IQR) if non-
normal and as frequency (%) for categorical variables.
Pair plots were produced for each variable to graphically
visualise the difference between on and off measure-
ments for each patient and to identify any relationship
between the outcome variables and being on/off β
blockers for those with normal lung function and those
with COPD. Variables were summarised by β blocker
status (on/off) and for normal lung function compared
with COPD and a comparison performed using a paired
t-test or a Mann-Whitney U-test when non-normal and
for categorical variables using a χ2 test or a Fisher’s exact
test when cell frequencies were insufﬁcient. A p value of
<0.05 was considered signiﬁcant.
Study power was based on change in VO2 peak at
anaerobic threshold (AT) which was the primary
outcome in our previous publication17 where we esti-
mated that 32 patients were required to detect a 10%
difference in VO2 at AT with 90% power and allowing
for 25% drop out. Separate study power was not calcu-
lated for the outcomes described here. All statistical ana-
lyses were performed using Stata V.13 (StataCorp., 2013.
Stata Statistical Software: release 13. College Station).
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RESULTS
We screened 252 participants, 55 completed the ﬁrst
assessment but 7 people then dropped out leaving 48
who completed both visits. No participant dropped out
due to symptoms possibly or likely related to β-blockade
—ﬁve performed the ﬁrst test taking β blockers but all
were taking them long term and two performed the ﬁrst
test not taking β blockers. From these 48 patients, 2 were
unable to perform IC at peak exercise reliably and a
further 8 did not produce guideline deﬁned lung func-
tion tests, so were excluded from this analysis leaving 38
participants. This is shown in ﬁgure 1. Six participants
already had a diagnosis of COPD.
From the 38 patients that completed all study
methods, 16 patients were already taking β blockers
(chronic group) and 22 were not taking β blockers
(acute group). Patients in the chronic group were taking
bisoprolol (8 participants), atenolol (5), propranolol
(1), carvedilol (1) and metoprolol (1) for hypertension
(9 participants), ischaemic heart disease (5) and atrial
ﬁbrillation (1) with the indication being unclear in one
participant. The CPET results have been published
previously.17
Baseline characteristics of the whole group (n=38)
and split into those with (n=15) and without (n=23)
COPD are shown in table 1. The lung function para-
meters presented were recorded at the visit off β block-
ers. There were no signiﬁcant differences between the
COPD group and non-COPD group in age, gender,
height, weight or BMI. As expected, there were signiﬁ-
cant differences in smoking and pack years. People with
COPD not only had a lower FEV1 and greater airﬂow
obstruction but were also more hyperinﬂated, had lower
airway speciﬁc conductance and showed dynamic
hyperinﬂation with exercise (a signiﬁcant fall in IC at
peak exercise).
Effect of β blocker
Signiﬁcant β blockade was achieved with a fall in heart
rate by 18 bpm.
The effect of β-blockade on cardiorespiratory para-
meters is shown in table 2. β-Blockade led to a small but
signiﬁcant fall in FEV1 in the whole group by a mean
100 mL (2.8% of predicted value), but there was no
further signiﬁcant change in any other lung function
measure.
There was no difference in the effect of β-blockade
according to whether the β blocker was already pre-
scribed (chronic group) or not normally prescribed
(acute group).
Effect of β blocker according to COPD status
In this unselected group, we found 15 people had
COPD. Six were previously diagnosed (3 already treated
with a β blocker) and 9 newly diagnosed (3 already
treated with a β blocker).
There was no difference in the effect of β-blockade on
lung function or dynamic hyperinﬂation when patients
with COPD were compared with those without COPD as
shown in table 3. In particular, the small change seen in
FEV1 was seen in people with and without COPD. Only
the COPD participants showed a fall in IC with exercise
(dynamic hyperinﬂation) and β-blockade had no signiﬁ-
cant impact on this.
No signiﬁcant difference was seen in peak exercise
measures when the COPD and non-COPD groups were
compared.
Figure 1 Consort diagram describing study flow.
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DISCUSSION
We have shown that β-blockade has a minimal effect on
lung function and dynamic hyperinﬂation, in vascular
surgical patients, regardless of the presence of mild to
moderate COPD. Combined with our published cardio-
pulmonary exercise testing results,17 this provides
further reassurance that the use of β blockers remains
safe in people with COPD. The high prevalence of
COPD suggests that vascular surgical clinics may repre-
sent a good place for COPD case ﬁnding using
spirometry.
It is known that bronchodilators, including β-agonists,
produce relatively rapid relaxation of airway smooth
muscle and improve expiratory ﬂow rate, but it is ques-
tionable whether this is the mechanism by which they
act in people with COPD where the prominent abnor-
malities are increased peripheral resistance and loss of
lung elastic recoil.23 In COPD patients, β-agonists have
been shown to reduce tidal inspiratory resistance,24 but
their main effect is by reducing end-expiratory lung
volume which allows the individual to exercise for
longer before they reach a critical and exercise limiting
inspiratory reserve volume.25 Hence, drugs that antagon-
ise airway β receptors and consequently reduce airway
calibre through their effect on airway smooth muscle
may have little effect on measures of airway function in
COPD patients as this is not predominantly determined
by airway smooth muscle. Our results are consistent with
this. There was a small effect on expiratory ﬂow mea-
sured by FEV1, which is consistent with previous
studies,14 but no effect on airﬂow assessed by FEV1/
FVC. Airway resistance and speciﬁc conductance were
unchanged, something which has not been published
previously, and β-blockade did not lead to a signiﬁcant
change in end-expiratory lung volume and magnitude of
dynamic hyperinﬂation during exercise. These results
are consistent with the minimal impact of perioperative
β-blockade on cardiopulmonary exercise parameters,
despite the high proportion of people with COPD in the
study.17
The study was designed, and powered, to establish the
effect of β-blockade on exercise parameters at AT and
peak ventilation.17 Participants were not selected
because they had COPD. The high prevalence of COPD
was higher than expected and exceeded 50% if only
current or ex-smokers were considered, so provided an
opportunity to compare the response to β-blockade
of people with COPD compared with a non-COPD
Table 1 Patient demographics and lung function recorded when they were not taking β blockers in the 38 participants and
split according to the presence or absence of chronic obstructive pulmonary disease
Whole group (n=38) Non-COPD (n=23) COPD (n=15) p Value
Age (years) 70 (5) 69 (6) 72 (4) 0.16
Male 33 (87%) 19 (83%) 14 (93%) 0.35
Female 5 (13%) 4 (17%) 1 (7%)
BMI (kg/m2) 29.1 (4.3) 29.3 (4) 28.6 (5) 0.72
Smoking
Current 10 (26%) 5 (22%) 5 (33%) <0.01
Ex-smoker 19 (50%) 9 (39%) 10 (67%)
Non-smoker 9 (24%) 9 (39%) 0
Pack years 31 (0–100) 23(0–80) 43.5 (12–100) 0.02
Current β blocker
No 22 (58%) 10 (43%) 12 (80%) 0.83
Yes 16 (42%) 13 (57%) 3 (20%)
FEV1 (L) 2.57 (0.69) 2.86 (0.61) 2.03 (0.55) <0.01
FEV1 (%) 94.8 (22.4) 105.4 (17.9) 75.0 (16.1) <0.01
FEV1/FVC 0.69 (0.12) 0.75 (0.05) 0.56 (0.08) <0.01
FVC (L) 3.68 (0.76) 3.71 (0.8) 3.61 (0.8) 0.68
FVC (%) 107.3 (18.7) 110 (19.9) 103.0 (16.8) 0.31
RV/TLC 46.2 (15) 42.4 (16.7) 52.5 (10.3) <0.01
TLCO (mmol/min/kPa) 6.28 (1.84) 6.44 (1.53) 6.04 (2.28) 0.52
TLCO (% predicted) 78.2 (20.1) 80.4 (16.5) 74.8 (24.9) 0.52
KCO (units/min) 1.17 (0.28) 1.24 (0.22) 1.06 (0.33) 0.41
KCO (% predicted) 91.3 (22.8) 94.9 (20.1) 85.7 (26.3) 0.23
Raw (kPa/s/L) 2.31 (0.88) 2.17 (0.74) 2.63 (1.05) 0.31
sGaw (kPa/s) 0.12 (0.05) 0.14 (0.05) 0.08 (0.03) <0.01
sRaw (kPa/s) 9.23 (3.62) 7.61 (3.12) 11.71 (2.76) <0.01
Resting IC (L) 2.91 (0.39) 2.71 (0.48) 2.99 (0.48) 0.28
Change in IC (L)—dynamic hyperinflation −0.09 (0.25) −0.02 (0.24) −0.20 (0.23) 0.02
Results are shown as mean±SD with the exception of pack years which is presented as mean (range).
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; KCO, transfer coefficient for carbon monoxide; Raw,
airway resistance; RV, residual volume; sGaw, specific airway conductance; sRaw, specific airway resistance; TLC, total lung capacity; TLCO,
diffusing capacity for carbon monoxide.
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population. It is striking that no difference in group
response was seen in any measure of lung function. The
majority of people had mild COPD, but it has been
shown previously these individuals have signiﬁcant venti-
latory impairment and gas exchange abnormalities
during exercise.26 Our results are consistent with this
work and our participants with generally mild COPD
showed signiﬁcant dynamic hyperinﬂation (IC fell by an
average of about 200 mL at peak exercise) and poorer
ventilatory function at AT and peak exercise before
β-blockade. However, β-blockade did not signiﬁcantly
worsen this. Ours is only the second study to examine
the effect of β-blockade on dynamic hyperinﬂation in
COPD patients and, along with the previous study,
has shown no signiﬁcant impact.15 However, our partici-
pants had less severe COPD (FEV1 75% vs 52% pre-
dicted) and fall in IC was greater in the previous study
probably due to greater disease severity and measure-
ment during endurance rather than incremental testing.
Consequently, although β-blockade did not lead to a
signiﬁcant difference in change in dynamic IC, when
comparing participants with and without COPD, we
cannot exclude this being apparent in a population with
more severe airway disease.
AAA is a recognised comorbidity in people with
COPD as is peripheral vascular disease with a prevalence
of 7% aged 55 years or younger increasing to 17% in
those 65 years or older.27 Six people were diagnosed
with COPD but after spirometry, a further nine current
or ex-smokers had signiﬁcant airﬂow obstruction; a
COPD prevalence of 39%. Although we were unable to
present full lung function results from a further 10 parti-
cipants, they all completed resting spirometry and 21 of
the 48 participants in this larger group had airﬂow
obstruction; a COPD prevalence of 44%. This is >50% of
only current or ex-smokers are considered. Although
our sample size is modest, this ﬁgure is higher than
many screening studies of high-risk individuals who had
chronic respiratory symptoms28 and spirometry screen-
ing in our local population29 and provides an oppor-
tunity for COPD case ﬁnding.
The study has a number of weaknesses, the foremost
of which being that participants were not selected
because they had COPD (or cardiac disease including
Table 2 Change in lung function and heart rate on and
off β blockers in the whole group of 38 participants
Lung function or heart rate
measurement Change p Value
FEV1 (L) −0.10 (0.23) 0.01
FEV1 (% predicted) −2.8 (5.9) <0.01
FVC (L) −0.10 (0.28) 0.98
FVC (% predicted) −0.8 (6.7) 0.45
FEV1/FVC −0.01 (0.05) 0.12
RV/TLC (% pred.) −0.8 (9) 0.63
Raw (kPa/s/L) 0.15 (0.67) 0.17
sGaw (kPa/s) 0 (0.03) 0.73
sRaw (kPa/s) 0.91 (1.89) <0.01
Resting IC (L) −0.01 (0.79) 0.96
Change in IC (L)—dynamic
hyperinflation
−0.03 (0.29) 0.5
Heart rate (bpm) −18 (19) <0.01
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity;
IC, inspiratory capacity; Raw, airway resistance; RV, residual
volume; sGaw, specific airway conductance; sRaw, specific airway
resistance; TLC, total lung capacity.
Table 3 The effect of β-blockade on change in lung function, dynamic hyperinflation and peak exercise according to whether
the individual had chronic obstructive pulmonary disease
Change; non-COPD (n=23) Change; COPD (n=15) p Value
FEV1 (L) −0.09 (0.32) −0.11 (0.18) 0.76
FEV1 (% predicted) −1.9 (5.9) −4.2 (6.5) 0.24
FVC (L) 0.01 (0.35) −0.09 (0.29) 0.30
FVC (% predicted) 0.2 (5.7) −2.2 (8.3) 0.32
FEV1/FVC −0.01 (0.06) −0.02 (0.06) 0.49
RV/TLC (% predicted) −2.1 (3.5) 0.5 (5.1) 0.27
Raw (kPa/s/L) −0.15 (0.66) −0.13 (0.84) 0.90
sGaw (kPa/s) 0.01 (0.05) 0 (0.01) 0.78
sRaw (kPa/s) 0.74 (1.89) 1.17 (1.87) 0.5
IC (L) at rest 0 (1.10) −0.05 (0.62) 0.46
VO2 at LT (mL/min) −0.21 (1.34) −0.54 (1.40) 0.54
VO2 at peak (mL/min) 0.11 (2.31) 0.21 (2.11) 0.90
Oxygen pulse (mL/beat) −1.52 (2.23) −2.17 (2.09) 0.42
VE/VO2 0.97 (3.90) 0.48 (3.63) 0.70
VE/VCO2 1.27 (2.33) 0.23 (1.72) 0.45
Workload (W) −1.1 (7.7) 4.3 (9.5) 0.08
Heart rate (bpm) −17 (11) −17 (7) 0.60
Change in IC (L)—dynamic hyperinflation 0.02 (0.24) −0.07 (0.30) 0.09
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; LT, lactate threshold; Raw, airway resistance; RV,
residual volume; sGaw, specific airway conductance; sRaw, specific airway resistance; TLC, total lung capacity; VCO2, maximal carbon
dioxide output; VE, minute ventilation; VO2, maximal oxygen uptake.
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heart failure) and the study was powered to assess a
difference in VO2 at AT in the whole group rather than
the outcomes we present. Hence, this is a post hoc
analysis and worthy of prospective conﬁrmation.
Notwithstanding, the results add to the evidence base
supporting the use of β blockers in people with COPD,
present data on plethysmographic lung function for the
ﬁrst time and add to the only previous publication
looking at the effect of β-blockade on dynamic hyperin-
ﬂation because our population had only modest spiro-
metric impairment.15 The other core limitation is we
cannot exclude more signiﬁcant dynamic hyperinﬂation
if the participants had more severe COPD and more
complete β blockade. We achieved signiﬁcant
β-blockade with a mean fall in resting pulse of 18 bpm,
but the protocol was pragmatic and the aim was not to
reduce heart rate to a level of 60–70 bpm promoted
in clinical cardiology practice.30 This is also reﬂected in
the modest fall in whole group systolic blood pressure
of 3 and 1 mm Hg diastolic. However, it seems unlikely
this would signiﬁcantly impact other lung function par-
ameter considering the lack of effect shown. The time
that the participant was taking β blockers was often
relatively short (excepting those individuals taking
β blockers chronically) but is consistent with many pre-
vious studies addressing the impact of β-blockade in
COPD patients. We did not switch individuals normally
taking β blockers from their usual therapy to bisoprolol
in order to mirror perioperative practice and to
reduce the time that β blockers were withdrawn from
people taking them chronically. This meant that partici-
pants were not all taking a cardioselective β blocker,
but we do not believe there was a signiﬁcant impact
on study results as 30/38 participants were taking
bisoprolol.
In summary, perioperative β blockade in people un-
dergoing vascular surgery appears safe generally and
more speciﬁcally in patients with coexistent mild to
moderate COPD. The impact on lung function is
minimal and there is no change in airway resistance, spe-
ciﬁc conductance or dynamic hyperinﬂation. However,
the prevalence of undiagnosed COPD is high and consid-
eration should be made to spirometric case ﬁnding
screening in this population.
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